Publications scientifiques

How reliable are ADC measurements? A phantom and clinical study of cervical lymph nodes

Moreau B [1], Iannessi A [1], Hoog C [1], Beaumont H [2] - Affiliations: [1] Department of Radiology, Centre Antoine Lacassagne, Nice, France. [2] Median Technologies, Valbonne, France.

The main objective of this study was to evaluate the variability of Apparent Diffusion Coefficient (ADC) measurements in vitro on a phantom and in vivo on cervical lymph nodes. The secondary objective was to understand and quantify ADC measurement errors, in view of correcting them in future studies.

Computer tomography-based body surface area evaluation for drug dosage: Quantitative radiology versus anthropomorphic evaluation

Antoine Iannessi [1], Hubert Beaumont [2], Christophe Hebert [3], Claire Dittlot [4], Marie Noëlle Falewee [5] - Affiliations: [1] Department of Radiology, Centre Antoine Lacassagne, Nice, France. [2] Median Technologies, Valbonne, France. [3] Department of Oncology, Centre Antoine Lacassagne, Nice, France. [4] Department of Gerontology, Centre Hospitalier Universitaire, Nice, France. [5] Department of Nutrition, Centre Antoine Lacassagne, Nice, France.

The measure of body surface area (BSA) is a standard for planning optimal dosing in oncology. This index is derived from a model having questionable performances. In this study, we proposed measurement of BSA from whole body CT images (iBSA). We tested the reliability of iBSA assessments and simulated the impact of our approach on patient chemotherapy dosage planning. Published: February 14, 2018

See publication

Quantitative imaging biomarker of disease progression in hepatocellular carcinoma and NASH

Nakano Y [1], Oubel E [1], Brag J [1], Doreille A [2], Lucidarme O [2]. Affiliations: [1] Median Technologies, Valbonne, France. [2] Hopital La Pitie Salpetriere, Paris, France.

NASH is a growing contributor to chronic liver disease and already represents the second highest cause of hepatocellular carcinoma in the United States. Current diagnosis and severity assessment typically relies on histopathological analysis from biopsy samples. With novel NASH therapies under development there is a need for reliable non-invasive assessment of disease progression. The aim of the study is to demonstrate the feasibility of using routine CT imaging protocols, combined with big data processing for extracting radiological signatures, for assessing disease progression in NASH patients. Poster presentation at: The NASH Biomarker Workshop 2017, May 5-6, 2017, Washington DC, USA